RxDoctor Payments Data

Karen Fitzgerald-Shelton, MD

Glaucoma Specialist · Murfreesboro, TNNPI 1437136959

Payments from drug & device makers

$10,807in general payments, 2019–2025

Across 250 payments — averaging $43.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$5K
  • AbbVie$3K
  • Sight Sciences, Inc.$841
  • Ocular Therapeutix, Inc.$487
  • Glaukos Corporation$447
  • Aerie Pharmaceuticals, Inc.$406
  • plus $1K from 13 others

What the payments were for

  • Travel & lodging$1,23511%
  • Food & beverage$9,34286%
  • Education$1852%
  • Gifts$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Tennesseeto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$262,394
Medicare patients
401
Services billed
1,545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate337$131,575
LumiganBimatoprost194$75,622
Brimonidine Tartrate556$43,520
CombiganBrimonidine Tartrate/Timolol128$38,267
VyzultaLatanoprostene Bunod74$28,805
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol159$25,334
RocklatanNetarsudil Mesylat/Latanoprost61$21,612
SimbrinzaBrinzolamide/Brimonidine Tart57$17,850
Prednisolone Acetate485$17,080
XiidraLifitegrast21$15,805
Alphagan PBrimonidine Tartrate59$15,772
Ketorolac Tromethamine430$14,824
RestasisCyclosporine14$8,309
MoxifloxacinMoxifloxacin Hcl250$7,210
Latanoprost776$6,996

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$406$153,187398 claims
AbbVieLumigan, Combigan, Alphagan P, Restasis$2,568$137,970395 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$40$44,61095 claims
AlconSimbrinza$4,866$17,85057 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$281$4,16812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Tennesseeon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Murfreesboro

Where these figures come from

Is this you, or does something look wrong? →